What NanoMedSyn does

NanoMedSyn SAS is a Montpellier-based, privately held biotechnology company founded around 2014-2015 that develops AMFA (Armed ManNose 6-Phosphate Functionalized Analogues) glycoligands, a proprietary chemical class designed to bind the mannose 6-phosphate receptor (M6PR) and route therapeutics into lysosomes. The company organizes its platform into three product modules: AMFA-engineered antibodies (mAb-AMFA) that act as first-in-class degraders of pathogenic antigens while retaining FcRn recycling; AMFA-modified nanoparticles (AMFA-NP) that broaden the tissue reach of biologics beyond the liver; and AMFA-conjugated enzymes (AMFA-Enzyme) for improved enzyme replacement therapy in rare lysosomal storage disorders such as Pompe disease. Its lead program, recombinant GAA-AMFA for Pompe disease, received EMA Orphan Drug Designation (EU/3/16/1726) in 2016.

The company generates revenue through technology platform licensing and co-development partnerships with biotechnology and pharmaceutical companies rather than through proprietary product sales, and it selectively advances internal programs to de-risk high-impact indications such as Pompe disease. Go-to-market relies on scientific conference participation (BIO Europe, BioFIT, Festival of Biologics, Antibody Engineering Europe) and direct enterprise partnering engagement; no public pricing, customer roster, or recurring revenue figures are disclosed. Funding to date has come predominantly from non-dilutive French public sources, including the Agence Nationale de la Recherche, the Occitanie Region, the Plan France Relance program, and Bpifrance (which classified the company as a DEEPTECH firm in 2021); no institutional equity venture round is documented.

NanoMedSyn operates from a single headquarters in Montpellier with 1-10 employees and is led by co-founder Dr. Marcel Garcia, formerly an INSERM research director who became CEO in July 2020. The company holds a patent estate covering AMFA composition, receptor engagement, and therapeutic applications, and has historical research ties to INSERM, the CNRS Max Mousseron Institute of Biomolecules, and a terminated 2018-2019 research agreement with Shire (later Takeda) in lysosomal storage disorders.

Name

NanoMedSyn

Legal name

NanoMedSyn SAS

Website

https://nanomedsyn.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

NanoMedSyn is a Montpellier-based private biotech that develops proprietary AMFA glycoligands targeting the mannose 6-phosphate receptor to deliver antibodies, nanoparticles, and enzymes into lysosomes, serving biopharmaceutical partners through licensing and co-development for rare diseases, oncology, and immunology.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology Licensing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Targeted protein degradation
• Drug delivery platforms
• Lysosomal storage disorders
• Enzyme replacement therapy
• Biopharmaceutical licensing

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Co-development: The company offers co-development, partnerships, and licensing around AMFA-enabled conjugation and delivery technologies while pursuing selected internal programs to de-risk high impact indications
2. Technology Platform Licensing: Flexible and modular AMFA glycoligands platform offering potential for rapidly developing differentiated delivery and degradation solutions across diverse disease areas

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NanoMedSyn develops AMFA (Armed Mannose 6-Phosphate Functionalized Analogues) glycoligands, a proprietary technology platform that specifically targets the mannose 6-phosphate receptor (M6PR) to enable precise intracellular delivery of therapeutics and lysosomal addressing of disease-driving antigens for degradation. The platform spans three modular product formats: AMFA-engineered therapeutic antibodies (mAb-AMFA) for targeted protein degradation, AMFA-modified nanoparticles (AMFA-NP) for delivery of biologics beyond the liver, and AMFA-conjugated enzymes (AMFA-Enzyme) for enhanced enzyme replacement therapy in lysosomal storage disorders such as Pompe disease.

Product overview

NanoMedSyn is a biotechnology company developing AMFA glycoligands as a modular technology platform that leverages the natural M6PR (mannose 6-phosphate receptor) pathway for targeted therapeutic delivery. The platform consists of three interconnected product modules: AMFA Glycoligands as the core chemical scaffold, which can be conjugated to (1) mAb-AMFA therapeutic antibodies for targeted protein degradation, (2) AMFA-NP therapeutic nanoparticles for precision delivery of biologics beyond the liver, and (3) AMFA-Enzyme conjugates for enhanced lysosomal delivery in enzyme replacement therapy. The technology enables new mechanisms of action for treating targets that were previously undruggable, with applications in oncology, immunology, inflammation, and metabolic disorders including Pompe disease.

Differentiator

Problem solved

Functional benefit

Products and services

• AMFA Glycoligands Platform A modular technology platform based on AMFA ligands that target the mannose 6-phosphate receptor (M6PR) to enable precise intracellular delivery of therapeutics and lysosomal addressing of disease-driving antigens for degradation, applicable across therapeutic antibodies, nanoparticles, and enzymes.
• mAb-AMFA Therapeutic Antibodies AMFA-engineered therapeutic antibodies that become first-in-class degraders capable of directing soluble or membrane pathogenic antigens to lysosomes for degradation, while retaining FcRn receptor recycling for prolonged half-life and standard antibody features including immunogenicity and ADCC.
• AMFA-NP Therapeutic Nanoparticles Therapeutic nanoparticles modified with AMFA that bind to M6PR and are internalized into extra-hepatic tissues, expanding the reach of RNA, enzymes, and other biologics with broader tissue distribution beyond the liver and improved cellular uptake in M6PR-overexpressing tissues including certain cancers.
• AMFA-Enzyme Replacement Therapy

Quantifiable outcome

• AMFA-engineered enzyme for Pompe disease received Orphan Drug Designation from EMA
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Shire (later Takeda)minorStrategic or Co-development Partner · 1 March 2018Research agreement for potential lysosomal storage disorder treatment. This collaboration was stopped in September 2019. Shire, specializing in rare diseases, partnered with NanoMedSyn to explore applications of AMFA technology for lysosomal storage disorders.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Ultragenyx Pharmaceutical: Ultragenyx is a rare disease biotech with a deep pipeline of enzyme replacement, gene therapy, and mRNA-based biologics — overlapping with NanoMedSyn's AMFA-Enzyme (ERT) and AMFA-NP (biologics delivery beyond liver) product modules.
• BioMarin Pharmaceutical: BioMarin is a leading rare disease biotech with active Pompe disease programs (notably BMN 307 gene therapy and co-developed AT-GAA with Amicus). Directly comparable to NanoMedSyn's AMFA-Enzyme Pompe program as both pursue enhanced enzyme/gene-based treatments for the same lysosomal storage disorder.
• Valerion Therapeutics: Valerion develops antibody-based therapies that leverage the mannose 6-phosphate receptor (M6PR) pathway for intracellular delivery to muscle and CNS — directly comparable to NanoMedSyn's AMFA glycoligand M6PR-targeting strategy for lysosomal delivery.
• Audentes Therapeutics (Astellas Gene Therapies): Audentes (now part of Astellas) develops gene therapies including AT132 for Pompe disease. Comparable to NanoMedSyn's Pompe disease focus and to its AMFA-Enzyme approach to address the same lysosomal enzyme deficiency through alternative delivery mechanisms.
• Amicus Therapeutics: Amicus develops AT-GAA (cipaglucosidase alfa + miglustat), a next-generation ERT for Pompe disease partnered with BioMarin. Closely comparable to NanoMedSyn's AMFA-Enzyme Pompe program in indication, mechanism category, and target patient population.

Broad incumbents

• Genentech (Roche): Genentech is the global leader in therapeutic antibody development across oncology, immunology, and inflammation. Comparable to NanoMedSyn's mAb-AMFA antibody engineering platform as a benchmark for antibody platform scale, clinical translation, and partnering economics.
• Takeda Pharmaceutical (Shire): Takeda, via its acquisition of Shire, operates one of the largest rare disease franchises and was NanoMedSyn's prior research partner (terminated 2019). Comparable as a large incumbent in lysosomal storage disorders and as a benchmark for partnership standards.
• Sanofi (Genzyme): Sanofi's Genzyme unit commercializes alglucosidase alfa (Myozyme/Lumizyme), the leading enzyme replacement therapy for Pompe disease. Comparable as the incumbent ERT benchmark that NanoMedSyn's AMFA-Enzyme program must differentiate against.

Emerging players

• Arvinas: Arvinas is a leader in targeted protein degradation (PROTACs) for oncology and immunology. Conceptually comparable to NanoMedSyn's mAb-AMFA degraders as both pursue first-in-class degradation-based mechanisms, though Arvinas uses the ubiquitin-proteasome pathway rather than lysosomal routing.
• Arcturus Therapeutics: Arcturus develops lipid nanoparticle-based delivery systems for mRNA and other nucleic acid therapeutics, expanding tissue distribution beyond the liver — directly comparable to NanoMedSyn's AMFA-NP nanoparticle module targeting extra-hepatic tissue delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoMedSyn